call webcast all you joining Thank And you, Glen. thank today. us and on for the the
While minutes, Craig detail I in commenting will few revenue. review our in want by a financial results on to begin
which for in noteworthy EPS launching of in with This a of revenue product. since is quarter revenue company approximately orders third the strong single shipped is particularly of year-over-year seasonally our by quarter was driven year-over-year. since typically This the was up the which soft. received XX% resulted growth very XX% Third largest is quarter $XXX,XXX number CGuard and CGuard
training of endarterectomy. relative program an reflects high artery carotid both data part clinical awareness disease. as and as impact to strong advantages growth conventional CGuard activities is of of the that of positive our having results physicians this surgery carotid the stents or Excellence carotid of These commercial conviction such well the give clinical as treating us believe on We our a strong degree a Centers physicians on increasing
quarter to we results into commercial in it continued our which new CGuard working territories, continue our significant markets third were driven strong introduce key focus opportunity. the While by on provides
we including regulatory most these South in Japan. noted As have be of to new the addressed China potential Taiwan, have that past, Korea, markets need requirements higher and
in end to In Brazil the our carotid is This seeks by A significant continue and year body last year. the real-world anticipate our artery experience fifth began initiative, year pricing currently of Brazil has world long-term that of next market using and EPS the early devices. interested we addition, Excellence vascular is strategy and as with in using COE growth approve of disease physicians Centers on largest the treats device. to attractive CGuard including component CGuard multifaceted visa late for of major regulatory the will which is or carotid surgeons that or provide the training in
to convert partners distribution key target our physicians to wish CGuard. enables This to they
with As the alternative vascular minimally which provides. have of majority a an we CGuard is treats out, surgical the invasive compared patients carotid pointed vast to the procedure, surgeon invasive endarterectomy
to is on its with who patients an for while and procedure surgical no all an of So of would risks. the efficacy education growth, undergo benefiting numbers CGuard associated safety have countless important enabling invasive driver longer
data KOL by to cases, to carotid hands-on double-layer and own COE live compelling our are carotid next-generation return stents, conferences, well The their educate data In devices the all but to an use train COE of in and ensuring clinic, available. back gather Key ready endarterectomy. number on not community ongoing and the we proctored data is clinical in important We clinics. brought compared are basis in then the them allowing Opinion and valuable the CGuard is publications clinical a into carotid always and presented COE clinicians clinical These for of the is Leaders or specific respected process educational generating other CGuard patient with on partners KOL real-world specialties. the that their sessions, conventional data CGuard also visiting clinical material only who to latest
our Today, first Spain, will be in extremely Poland UK. the Germany and with and we month, we Last opened Slovenia COEs results. soon opening COE in Italy, one have positive in opened
in to a key As long possible a COEs. and our for result CGuard this of population program way goal to by patient It's to a participate our list Excellence go waiting broadest making and available awareness toward Centers utilization. driving physicians make happening initiative, this will our have of we now the
to helping is also our raise publications addition and presentations the additional CGuard In to data clinical supporting value COEs, of of awareness.
safety During quarter, stent CGuard the and from level performance a for and was the trials disease Heart of evidence first carotid the the continue asymptomatic World Data extensive mesh stents. carotid versus four meta-analysis add the time at and third on of we other Federation recent European Society the included symptomatic patient highlighting presented Cardiology. artery joint patients of XXX body that to Congress of to
who safety rate, highly endarterectomy, EPS superiority double-layer compared statistically as At with devices a well incidence carotid advantage significant p-value devices, and mesh efficacy of surgical The that stent double-layer X.XXX for both critical of in reduced EPS on compared X.X% equality results stenosis carotid publish CGuard or the CGuard the competitor endpoint. disease. showed this to CGuard competitive one-year follow-up, second-generation and in carotid artery current as covered demonstrates treatment data stents a with another experienced a X% mesh first-generation superiority as carotid meaning of stent patients to or to clinical thrombosis covered intestine or received a in
treated the in and competitive death devices. greater trends CGuard Professor PiotrMusialek endpoint positive In his session, at a stroke devices follow-up presented reduction another XX% for After CGuard. XXX a at to XX-months term compared paradigm and reduction stroke solid, any to XX and also XX% demonstrated days. XX patients competitors of demonstrated compared death occurred CGuard ongoing or and theater results from The major stent were X% with study. no combined at mortality infarction myocardial with short same presentation than occurred than strokes showing less in overall days XXX clinical long
or Additionally, followed benefit. sustained reported related showing now a no events XX Professor thus device years PiotrMusialek patients to four-year on procedure out and adverse four related
now patients carotid carotid The of across interventional Professor ongoing the is XXX same consistent stenosis. Turning clinical asymptomatic registry Real included from in safety artery clinical with for Vascular and presented Registry with prevention stroke the Journal. Italian up Italy in evidence included World XX study on different the XX follow preliminary stent in The European duplex results surgeons, CGuard Journal large ultrasound IRONGUARD disease, risk subjects embolization going with centers vascular cerebral of including Surgery. II that the prestigious and paper specialties increased cardiologists. paradigm stroke month and Heart Also publications. the published trial that published in was treat were prevention treated to PiotrMusialek and interventional symptomatic the to EPS and physicians radiologists
multicenter, EPS strongly very support as compelling practice complications. peer-reviewed to efforts real-world important these large this major in in procedural accepted ongoing journals with no registry, or we XX-day awareness associated safety clinical data into of is These advantages. multi-specialty our routine that parry concluded paper the of commercial The work use CGuard neurologic raise
risk in new been All important paradigm for of factor generated support breakthrough the to which data a leading an has EPS is fact representing carotid continues disease, of the the that today artery that the stroke. CGuard remains treatment
CGuard or untreated. opportunity near-term based diagnosed who we grow We approximately carotid million currently endarterectomy. people conventional This are address market could out the exponentially estimate patients $X if stents a are can convert there billion who solely carotid either with can but treated the opportunity X.X on
we add to key As strategy. a enquiries; we the queries And we been focus place proactive growth the business pillar. second plan resources been always to call, in discussed importantly, focused assess recognize business strategy more Business have development need with recent on that more development of implement our development has and inbound receiving. to long-term quarter effectively a we more our this pillar additional
intellectual property, innovations. In IP two proprietary we we fiber single to September, announced were stent our covering that global our mess-jacket substantial protect to granted to franchise technology. continue now Turning reinforce our new we US patents
to The expandable an advantageously method in of a alluded of method a mesh treat jacket and artery. or therapeutically effective with first, a coronary a stent disorder stenting carotid active a providing agent pharmaceutical assembly includes amount of that the
into both patent-protected and generally. fields to IP of the expandable assembly peripheral The method with and treat new vascular and mesh an which differentiated stenting second aneurysm stent and us expandable where includes should devices. help expand the patent highly This stent is adapted jacket stent an neurovascular the covers
a turning an Before to take IDE review Craig to our call moment information. we to or over had additional the September, announced to Device submission. want financials, that Exemption Investigational provide update US FDA the In requested the on I
further past, in provide submission testing we not information the of additional bench requesting unusual to FDA the the is the we support to noted with requested work information. agency IDE continue As in and an closely
been working remaining the interactive through resolve have requests. to process outstanding We very a cooperative and
approval with Importantly, the which of requirement to the on study the concurred clinical data has provides device. market specificity the clinical design FDA support the
that our the confirming body IDE safety be approved. profile significant optimistic of CGuard, the will Given remain evidence we of
With Craig that I'll turn over to financials. for a the of call the review
